GNAS1 T393C polymorphism and disease progression in patients with malignant melanoma

European Journal of Medical Research

Volumn 15, Issue 10, 2010, Pages 422-427

  Frey, U H ^a   Fritz, A ^b   Rotterdam, S ^b   Schmid, K W ^a   Potthoff, A ^b   Altmeyer, P ^b   Siffert, W ^a   Brockmeyer, N H ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

G protein; Melanoma; Polymorphism; Prognostic factor

Indexed keywords

ADULT; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENOTYPE; GNAS1 GENE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78349242488     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-15-10-422     Document Type: Article

References (36)

1. Rebmann V, Ugurel S, Tilgen W et al. Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer. 2002; 100: 580-5. (Pubitemid 34816159)
2. Bosserhoff AK, Kaufmann M, Kaluza B et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 1997; 57: 3149-53. (Pubitemid 27351728)
3. Ugurel S, Rappl G, Tilgen W et al. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001; 19: 577-83.
4. Ugurel S, Rappl G, Tilgen W et al. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res. 2001; 7: 1282-6.
5. Hauschild A, Engel G, Brenner W et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol. 1999; 140: 1065-71.
6. Hauschild A, Engel G, Brenner W et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology. 1999; 56: 338-44.
7. Guo HB, Stoffel-Wagner B, Bierwirth T et al. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer. 1995; 31A: 924-8.
8. Henze G, Dummer R, Joller-Jemelka HI et al. Serum S100 - a marker for disease monitoring in metastatic melanoma. Dermatology. 1997; 194: 208-12.
9. Streit S, Mestel DS, Schmidt M et al. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer. 2006; 94: 1879-86.
10. Tsao H, Zhang X, Fowlkes K et al. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res. 2000; 60: 1800-4.
11. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-54.
12. Okamoto I, Roka F, Krogler J et al. The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. J Invest Dermatol. 2006; 126: 2242-6.
13. Frey UH, Eisenhardt A, Lummen G et al. The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14: 871-7.
14. Frey UH, Alakus H, Wohlschlaeger J et al. GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res. 2005; 11: 5071-7.
15. Frey UH, Nuckel H, Sellmann L et al. The GNAS1 T393C Polymorphism Is Associated with Disease Progression and Survival in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2006; 12: 5686-92.
16. Frey UH, Lummen G, Jager T et al. The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. Clin Cancer Res. 2006; 12: 759-63.
17. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature. 1997; 390: 88-91.
18. Krumins AM, Barber R. Examination of the effects of increasing Gs protein on beta2-adrenergic receptor, Gs, and adenylyl cyclase interactions. Biochem Pharmacol. 1997; 54: 61-72.
19. Yang X, Lee FY, Sr., Wand GS. Increased expression of Gs(alpha) enhances activation of the adenylyl cyclase signal transduction cascade. Mol Endocrinol. 1997;11: 1053-61.
20. Yang W, White B, Spicer EK et al. Complex haplotype structure of the human GNAS gene identifies a recombination hotspot centred on a single nucleotide polymorphism widely used in association studies. Pharmacogenetics. 2004; 14: 741-7.
21. Siffert W, Forster P, Jockei KH et al. Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol. 1999; 10: 1921-30.
22. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19: 3635-48.
23. Pho L, Grossman D, Leachman SA. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol. 2006; 18: 173-9.
24. Nikolova PN, Pawelec GP, Mihailova SM et al. Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunol Immunother. 2007; 56: 371-9.
25. Martinez-Escribano JA, Moya-Quiles MR, Muro M et al. Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res. 2002; 12: 465-9.
26. Buettner PG, Leiter U, Eigentier TK et al. Development of prognostic factors and survival in cutaneous melanoma over 25 years: An analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Cancer. 2005; 103: 616-24.
27. Duan J, Wainwright MS, Comeron JM et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet. 2003; 12: 205-16.
28. Capon F, Allen MH, Ameen M et al. A synonymous SNP of the corneodesmosin gene leads to increased mRNA stability and demonstrates association with psoriasis across diverse ethnic groups. Hum Mol Genet. 2004; 13: 2361-8.
29. Tierney MJ, Medcalf RL. Plasminogen activator inhibitor type 2 contains mRNA instability elements within exon 4 of the coding region. Sequence homology to coding region instability determinants in other mRNAs. J Biol Chem. 2001; 276: 13675-84.
30. Dumaz N, Light Y, Marais R. Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms. Mol Cell Biol. 2002; 22: 3717-28.
31. Kadekaro AL, Kanto H, Kavanagh R et al. Significance of the melanocortin 1 receptor in regulating human melanocyte pigmentation, proliferation, and survival. Ann N Y Acad Sci. 2003; 994: 359-65.
32. Hunt G, Todd C, Cresswell JE et al. Alpha-melanocyte stimulating hormone and its analogue Nle4DPhe7 alpha-MSH affect morphology, tyrosinase activity and melanogenesis in cultured human melanocytes. J Cell Sci. 1994; 107 (Pt 1): 205-11.
33. Dumaz N, Hayward R, Martin J et al. In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP Signaling. Cancer Res. 2006; 66: 9483-91.
34. Karasarides M, Chiloeches A, Hayward R et al. B-RAF is a therapeutic target in melanoma. Oncogene. 2004; 23: 6292-8.
35. Hingorani SR, Jacobetz MA, Robertson GP et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003; 63: 5198-202.
36. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-54.